Growth Hormone Deficiency Clinical Trial
Official title:
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study, to Assess Tolerability, Safety, Pharmacokinetic and Pharmacodynamic Profiles of hGH-ViaDerm™ System in Adult Subjects With Growth Hormone Deficiency
NCT number | NCT00455260 |
Other study ID # | GH-VD-102 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | April 2, 2007 |
Last updated | August 30, 2013 |
Start date | April 2007 |
This study aims to examine the safety, tolerability and pharmacokinetics of transdermal delivery of human Growth Hormone (hGH or somatropin) using the ViaDerm device in adult patients with Growth Hormone Deficiency Syndrome.
Status | Completed |
Enrollment | 60 |
Est. completion date | |
Est. primary completion date | October 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 60 Years |
Eligibility |
Inclusion Criteria: Ages Eligible for Study: 20 Years - 60 Years, Genders Eligible for Study: Both 1. Clinical diagnosis of Adult Growth Hormone Deficiency (AGHD) meeting one of the following criteria: - Three or more additional pituitary hormone deficiencies, based on well documented medical history from up to 10 years prior to screening, and/or serum IGF-1 levels below 2 SD from normal level, measured up to 4 months prior to screening. - One or two additional pituitary hormone deficiencies with one GH stimulating test performed within 10 years prior to screening: Insulin Tolerance test with GH levels less than 5.1 µg/L or ARG-GHRH with GH levels less than 4.1 µg/L. - Isolated GH deficient subjects with two well-documented GH stimulating tests performed within 10 years prior to screening. Insulin Tolerance test with GH levels less than 5.1 µg/L or ARG-GHRH with GH levels less than 4.1 µg/L. - In childhood onset AGHD, confirmation of GHD following attainment of full height. 2. Subjects using hormone replacement therapy for additional pituitary deficits must be on an optimized treatment regimen for at least three months prior to screening. 3. Willing and able to provide written informed consent prior to performing any study procedures. Exclusion Criteria: 1. GH therapy within one month prior to study entry. 2. For female subjects: pregnancy or lactation or use of oral contraception or unacceptable method of contraception throughout the study. 3. Active acromegaly in the last 5 years. 4. Carpal tunnel syndrome. 5. Prader-Willi syndrome. 6. Active Cushing's syndrome within the last 12 months. 7. Non-compliance for upper arm SC injection or patch application. 8. Skin color or tattoo that would not enable detection of erythema. 9. Upper extremities with skin marks, bruises, cuts, abrasions on the upper arm. 10. Dense and dark hair growth on upper extremities. 11. History of skin hypersensitivity and/or allergies. 12. Known hypersensitivity to somatropin or mannitol 13. Evidence of active malignancy. 14. Previous use of chemotherapy, immunosuppressive or radiation therapy, except for treatment of pituitary disease. 15. Serum glucose (fasting) > 126 mg/dl. 16. Known or suspected HIV-positive subjects or subjects with advanced diseases such as AIDS, Hepatitis C, Hepatitis B or tuberculosis. 17. Subjects who, based on the investigator's judgment, have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. Conditions may include cardiovascular, vascular, pulmonary, hepatic, renal, or neurological disease, as determined by medical history, physical examination, laboratory tests or ECG. 18. BMI < 19 and = 35 kg/m2. 19. Weight reducing drugs or appetite suppressants. 20. Estrogen replacement therapy except transdermal patch. 21. Any psychological condition which may influence the compliance with the study requirements. 22. Unstabilized antidepressant or antipsychotic medication therapy within 2 months prior to screening. 23. Subjects with a known history of alcohol abuse. 24. Subjects who received blood or plasma derivatives in the three months preceding screening. 25. Subjects who donated blood in the preceding three months of screening or intend to make a blood donation during the study, or within the three months following the study completion. 26. Subjects who have participated in another clinical study of any kind (drug or device) in the one month prior to screening. 27. Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Teva Neuroscience, Inc. | Teva Pharmaceutical Industries, TransPharma Medical |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AE | 36 days | Yes | |
Primary | Laboratory values | 36 days | Yes | |
Primary | Vital signs | 36 days | Yes | |
Primary | ECG | 36 days | Yes | |
Primary | Patch application site reaction: Skin irritation- erythema, edema | 36 days | Yes | |
Primary | Patch application site reaction: Pain - Visual Analogue Scale | 36 days | Yes | |
Primary | Proportion of subjects (%) who discontinue the study | 36 days | Yes | |
Primary | Proportion of subjects (%) who discontinue the study due to AEs | 36 days | Yes | |
Primary | Pharmacokinetics: Somatropin exposure including Cmax, Tmax, AUC, AUC, Ke, and T1/2. | 36 days | No | |
Primary | Pharmacodynamics: Human IGF-1 levels and AUC. | 36 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02243852 -
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
|
N/A | |
Completed |
NCT01440686 -
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00990340 -
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
|
Phase 4 | |
Completed |
NCT00149708 -
Consequence of Lifetime Isolated Growth Hormone Deficiency
|
N/A | |
Completed |
NCT00235599 -
The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.
|
N/A | |
Completed |
NCT00459940 -
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
|
N/A | |
Completed |
NCT01157793 -
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
|
Phase 4 | |
Completed |
NCT00004365 -
Study of Pituitary Size and Function in Familial Dwarfism of Sindh
|
N/A | |
Recruiting |
NCT00227253 -
Chromosome 18 Clinical Research Center
|
||
Recruiting |
NCT04121780 -
Growth Hormone Replacement Therapy for Retried Professional Football Players
|
Phase 2 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT01090778 -
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
|
Phase 2 | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT01062529 -
Peripheral Metabolic Effects of Somatostatin
|
N/A | |
Completed |
NCT00616278 -
National Cooperative Growth Study in CKD
|
N/A | |
Completed |
NCT02693522 -
Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
|
Phase 3 | |
Recruiting |
NCT02908958 -
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
|
Phase 4 | |
Terminated |
NCT01243892 -
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
|
N/A | |
Withdrawn |
NCT00638287 -
Inter-Assay Growth Hormone and IGF-I Variability
|
N/A | |
Completed |
NCT00957671 -
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
|
Phase 4 |